Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2020 | Fedratinib for myelofibrosis

Claire Harrison • 5 Jun 2020
EHA 2020
Myelofibrosis Myeloproliferative Neoplasms Fedratinib Ruxolitinib
FREEDOM JAKARTA

Claire Harrison, MD, DM, FRCP, FRCPath, of Guy’s and St Thomas’ NHS Foundation Trust, London, UK, discusses the use of fedratinib for myelofibrosis, highlighting data from the JAKARTA (NCT01437787) and FREEDOM (NCT03755518) trials. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Claire Harrison

Real-world data on the treatment of adolescents and young adults with MPNs 2:49
Real-world data on the treatment of adolescents and young adults with MPNs
Claire Harrison • 23 Jun 2025
Evolving strategies in MPNs: big data analysis, wearable devices, & targeted therapies 3:20
Evolving strategies in MPNs: big data analysis, wearable devices, & targeted therapies
Claire Harrison • 23 Jun 2025
72-week results from MANIFEST-2: pelabresib plus ruxolitinib in JAK inhibitor-naive myelofibrosis 2:17
72-week results from MANIFEST-2: pelabresib plus ruxolitinib in JAK inhibitor-naive myelofibrosis
Claire Harrison • 23 Jun 2025
The influence of clone size on treatment decisions and disease progression in MPNs 3:01
The influence of clone size on treatment decisions and disease progression in MPNs
Claire Harrison • 23 Jun 2025

Related Videos

Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach 2:14
Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach
John Mascarenhas • 4 Sep 2025
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors 1:19
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors
John Mascarenhas • 3 Sep 2025
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS 10:06
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS
Asfand Yar Cheema • 5 Sep 2025
The value of fedratinib for the treatment of patients with MF in the second-line setting 1:19
The value of fedratinib for the treatment of patients with MF in the second-line setting
Francesco Passamonti • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals